
13/09/2025
✨ Switching from Mounjaro to Wegovy ✨
With the recent rise in the cost of Mounjaro (tirzepatide), we’re seeing more patients in the maintenance stage of their weight-loss journey transition to Wegovy (semaglutide).
The two medications work a little differently:
• Mounjaro is a dual GIP/GLP-1 agonist, acting on two incretin pathways — which is why studies often show slightly greater average weight loss.
• Wegovy is a GLP-1 receptor agonist, working mainly by suppressing appetite. When paired with reduced calorie intake and increased activity, it still produces significant weight loss.
While Wegovy’s weight-loss percentage is typically lower than Mounjaro’s, it remains a highly effective option — particularly for those aiming to maintain results or gradually taper off medication. For some, it’s also a more tolerable and cost-effective choice.
📚 Good news: Recent studies support that patients can safely make a direct switch between the two, under medical supervision. We also have comparison dosing guides to help ensure a smooth transition.
If you’re considering switching or want personalised guidance, feel free to reach out or send me a DM